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ABSTRACT Dihydrofolate reductase (DHFR; EC 1.5.1.3)
is required in folate metabolism for the synthesis of purines,
thymidine, and glycine. Although there have been several
reports of induction ofDHFR enzyme by methotrexate (MTX),
a drug that competitively inhibits DHFR, there are no studies
reported that examine the effect of MTX on DHFR gene
transcription. We have examined the effect ofMTX and other
inhibitors of DNA synthesis on DHFR transcription using a
transient expression assay. MTX stimulates transient expres-
sion in a concentration-dependent manner from a hamster
DHFR promoter construct containing 150 base pairs 5' to the
start of transcription. Addition of either tetrahydrofolate or
hypoxanthine plus thymidine prevents the promoter induction
in response to MTX, suggestiug that stimulation by MTX
results from inhibition of these metabolites. Furthermore, two
other antimetabolic drugs-fluorodeoxyuridine and hydroxy-
urea-als stimulate the DHFR promoter in a concentration-
dependent manner. In contrast, aphidicolin, which blocks cell
growth through inhibition ofDNA polymerase a, has no effect
on theDHFR promoter. The potential relevance ofthese results
to cross-resistance to chemotherapeutic agents and to the
process of gene amplification is discussed.
Dihydrofolate reductase (DHFR; EC 1.5.1.3) catalyzes the
reduction of folate to dihydrofolate and then to tetrahydro-
folate. Reduced folates are required cofactors for de novo
synthesis of thymidylate, purines, and glycine. DHFR is
required for maintenance of cell growth and is thus expressed
in virtually all growing cells. The chemotherapeutic agent
methotrexate (MTX) is a dihydrofolate analog that binds
DHFR, thereby inhibiting its enzymatic activity and prevent-
ing cell growth. Chronic MTX treatment can lead to MTX
resistance; one mechanism whereby cells become resistant is
amplification of the DHFR gene, which results in increased
DHFR mRNA and protein levels (1). Very little is known
about the early events that occur between MTX treatment
and gene amplification.
Several laboratories have reported that DHFR enzyme
levels are elevated by treatment of cells with MTX (2-4) or
hydroxyurea (4) and that the stimulation by hydroxyurea is
due to elevated mRNA levels (4). The drug-induced increase
in DHFR mRNA levels may result from increased transcrip-
tion, decreased mRNA degradation, or accumulation of
mRNA due to blockage of cells at the G1/S boundary of the
cell cycle, when DHFR gene transcription is maximal (5, 6).
The stimulation ofDHFR byMTX and hydroxyurea may also
be the result of inhibition of DNA synthesis, resulting in
rereplication of the gene (i.e., gene amplification) and sub-
sequent elevated expression from the increased number of
transcription templates (7). Consistent with this idea, hy-
droxyurea, which blocks DNA replication, and hypoxia and
UV irradiation, which damage DNA, all have been found to
increase the frequency ofDHFR gene amplification (8-10).
Transcriptional activation ofthe DHFR gene by MTX is an
equally plausible hypothesis to explain the increased mRNA
and enzyme levels, and this possibility has not been carefully
addressed. We have previously characterized the protein/
DNA interactions in the DHFR promoter that are required
for efficient and accurate transcription (11-13). There are
several GC elements (shown in Fig. 1), consensus binding
sites for the transcription factor Spl, present in the hamster
DHFR promoter that are essential for DHFR transcription
(11) and that control transcription start site utilization (12).
This (G+C)-rich promoter motif is common to many so-
called housekeeping genes as well as several growth factor
and growth factor receptor genes and oncogenes (ref. 11 and
references therein). There are also two overlapping recogni-
tion sites for the transcription factor E2F that lie immediately
3' to the major start of transcription; mutation of these sites
results in a significant reduction of transcription (13). The
functional significance of a nucleotide sequence is often
suggested by evolutionary conservation; the 5' flanking re-
gions of the human (14), murine (15), and hamster (16, 17)
DHFR genes exhibit a high degree of sequence conservation,
particularly within the binding sites for the transcription
factors Spl and E2F. Because the DHFR promoter is similar
to those ofmany housekeeping genes, it is possible that many
other genes in this class may also be transcriptionally acti-
vated by antimetabolic drugs, such as those discussed herein.
We have examined the effects of treatment with MTX and
other inhibitors of DNA synthesis on DHFR promoter ac-
tivity to address the question of whether these agents tran-
scriptionally activate theDHFR gene. In this paperwe report
that treatment of Chinese hamster ovary (CHO) cells with
MTX increases expression from a DHFR promoter chloram-
phenicol acetyltransferase (CAT) construct. We show that
stimulation by MTX can be inhibited by addition of 5-meth-
yltetrahydrofolate, which obviates the requirement for
DHFR to reduce folates. This increase can also be prevented
by addition of hypoxanthine plus thymidine, which supplies
the two end-products of the biosynthetic pathway involved in
DNA replication that is inhibited by MTX. We also examined
the effect of three other DNA synthesis inhibitors
aphidicolin, fluorodeoxyuridine, and hydroxyurea-on the
DHFR promoter. We present data to demonstrate that treat-
ment of cells with aphidicolin does not affect DHFR pro-
moter activity, whereas hydroxyurea or fluorodeoxyuridine
treatments stimulate the DHFR promoter in a concentration-
dependent manner. Thus, the DHFR promoter is stimulated
by at least three different antimetabolites, and the stimulation
is not simply the result of inhibition of cell growth.
Abbreviations: DHFR, dihydrofolate reductase; MTX, methotrex-
ate; CAT, chloramphenicol acetyltransferase; CHO, Chinese ham-
ster ovary; AdMLP, adenovirus major late promoter; DMSO, di-
methyl sulfoxide; ANOVA, analysis of variance.
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FIG. 1. DHFR promoter transient expression vector. pDHF/CAT was constructed by cloning the hamster DHFR promoter fragment from
nucleotide position -210 to -23 (relative to ATG = position 1) 5' to the bacterial CAT gene and simian virus 40 poly(A) signal in a pUC18 vector.
The major start site ofDHFR transcription (bold arrow) is at nucleotide position -63, and nucleotide position -107 is the minor start site. GC
boxes are indicated by stippled boxes and are numbered in the text I-IV, proximal to distal; open boxes indicate additional conserved sequence
elements. Binding sites for the transcription factor E2F are indicated by the hatched box.
EXPERIMENTAL PROCEDURES
Construction of Clones. The DHFR promoter constructs
were derived from a genomic CHO clone previously de-
scribed (16). The construct that is used in the present studies,
designated pDHF/CAT, contains hamster DHFR promoter
sequence from positions -210 to -23 base pairs (bp) relative
to the start of translation (i.e., -147 to +40 relative to the
major transcription start) cloned 5' to the coding sequence for
the bacterial CAT gene fused to a poly(A) sequence from the
simian virus 40 large tumor antigen (11). The clone used as a
control consists of the adenovirus major late promoter fused
to CAT (AdMLP/CAT) (18) in the same expression vector
construct.
Cell Culture and Transfections. CHO cells were grown in
monolayer in Eagle's minimal essential medium (MEM)
supplemented with 5% fetal bovine serum, nonessential
amino acids, glutamine, and penicillin/streptomycin. The
doubling time of CHO cells is -20 hr under these growth
conditions. Twenty-four hours prior to transfection, cells
were plated at -5 x 105 per 10-cm plate in Eagle's MEM
supplemented with 5% dialyzed fetal bovine serum (dFBS).
Promoter-CAT constructs were transfected by the calcium
phosphate coprecipitation method essentially as described by
Graham and van der Eb (19). Within each experiment, a
single DNA precipitate at a concentration of 10 Ag/ml was
formed for each DNA construct. The individual plates were
rinsed and the monolayer was drained; 0.5 ml of DNA
precipitate (5 ,ug) was added dropwise to the individual
plates. Complete medium containing 5% dFBS was added
after 30 min at room temperature. Four hours later, the
monolayer was washed and complete medium containing
dFBS was added to the cells. Test agents were added directly
to the medium as indicated in the figure legends. MTX was
obtained from the Drug Synthesis and Chemistry Branch of
the National Cancer Institute; MTX was reconstituted in 0.1
M NaOH in a 50 mg/ml stock solution that was diluted in
water for use and stored in the dark at -20°C. Aphidicolin,
hydroxyurea, and fluorodeoxyuridine were obtained from
Sigma. Aphidicolin was reconstituted in dimethyl sulfoxide
(DMSO) at 10 mg/ml; DMSO was added to cells in the
volumes used for aphidicolin treatment to control for vehicle
effects. Hydroxyurea and fluorodeoxyuridine were reconsti-
tuted in water at 1 M and 100 mM, respectively.
Assay for CAT Activity. Following a 48-hr incubation, cells
were harvested and subjected to freeze-thaw lysis. Lysates
were assayed for protein content by the Bradford (20) assay.
CAT activity was measured by a fluor-diffusion assay using
[acetyl-3H]acetyl CoA (200 mCi/mmol; 1 Ci = 37 GBq;
NEN), essentially as described by Neumann et al. (21),
except that 0.4 ,Ci of [3H]acetyl CoA plus 40 AM unlabeled
acetyl CoA were used per assay. Twenty micrograms of
protein cell extract was assayed, and CAT activity was
calculated as pmol ofproduct acetylated per ,ug ofprotein. To
make comparisons between experiments, data are presented
as relative CAT activity, with wild-type untreated CAT
expression normalized to 1.
RESULTS
Effects of MTX on DHFR Promoter Activity. The hamster
DHFR promoter construct used in the experiments (pDHF/
CAT) reported in this manuscript contained DNA sequence
from the positions -210 to -23 bp relative to ATG. The
sequence elements in this construct that are highly conserved
in the mouse and human DHFR promoters (shown in Fig. 1)
consist of four GC boxes (stippled boxes), two 20-bp regions
3' to boxes I and II (open boxes), and two overlapping
recognition sites for the transcription factor E2F (hatched
box). Each of these elements has been shown to be func-
tionally important for constitutive activity of the hamster
DHFR promoter (11-13). Maximal promoter activity is ob-
tained with this construct; constructs with additional 5'
sequence are equally active in transfection experiments (11),
whereas deletion or mutation of GC boxes I, II, or III
significantly reduces transcriptional efficiency (12).
To determine the effect of MTX on the DHFR promoter,
CHO cells were transfected with pDHF/CAT and treated
with MTX at 0.05, 0.1, 0.15, 0.2, and 0.25 /ug/ml. A linear
increase in CAT activity was observed in response to MTX
treatment from 0.05 to 0.2 pug/ml (Fig. 2). In cells treated with
0.2 ,gg of MTX per ml of medium, there was an -5-fold
stimulation of CAT expression in this experiment. The max-
imal stimulation in the 20 times that MTX has been tested
ranged from 4- to 20-fold.
To determine whether general transcription is stimulated
by MTX treatment, the AdMLP (18), which bears no se-
quence homology to the DHFR promoter, was tested. As
shown in Fig. 2, CAT expression under the control of the
AdMLP was not stimulated by MTX treatment ofCHO cells.
Thus, stimulation of the DHFR promoter by MTX is not the
result of a general transcriptional response.
Metabolic Signals. In an effort to understand the signal(s)
involved in the elevation ofDHFR promoter activity, various
substances that obviate the requirement for certain metabolic
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FIG. 2. Effect of MTX on transient expression from the DHFR
promoter. pDHF/CAT or AdMLP/CAT plasmid constructs (5 ,g
each) were transfected by the calcium phosphate procedure into
CHO cells. MTX was added to the medium at the concentrations
indicated. After 48 hr, cells were harvested and assayed for protein
concentration and CAT activity was measured in cellular lysates on
equal amounts of protein. CAT activity of untreated cells was
assigned a relative value of 1. These results are representative of
three repetitions of this experiment.
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5-methyltetrahydrofolate, which circumvents the cellular re-
quirement for DHFR, restored cell growth (Fig. 3B) and
blocked the stimulation ofDHFR promoter activity (Fig. 3A).
5-Methyltetrahydrofolate restores tetrahydrofolate pools,
which are specifically blocked by MTX; however, 5-meth-
yltetrahydrofolate also competitively inhibits MTX transport
into cells (22,23). To address the possibility that the inhibition
ofCAT activity was due to decreased MTX uptake rather than
to activation of the promoter, we added hypoxanthine and
thymidine, alone and in combination with MTX, to circumvent
the inhibition of purine and thymidine biosynthesis, respec-
tively, by MTX. Neither hypoxanthine nor thymidine has been
shown to affect MTX transport, but both of these compounds
have been shown to rescue cells from MTX treatment (24).
Both 17.6 ,uM hypoxanthine and 100 gM thymidine alone
inhibited stimulation of the DHFR promoter by MTX, hypo-
xanthine to a greater extent than thymidine. When both agents
were added together, stimulation by MTX was completely
blocked, suggesting that the stimulated transcription is medi-
ated by decreased purine and thymidine metabolism (Fig. 3A).
When added in the absence of MTX, neither 5-methyltetrahy-
drofolate, thymidine, nor hypoxanthine significantly affected
CAT expression (data not shown).
Relatioship Between Effects on Cell Growth and Promoter
Stimniation. Treatment of cells with MTX alone stimulated the
DHFR promoter in a concentration-dependent manner (Figs.
2 and 3A, groupC). In an effort to determine whether the effect
of MTX was due to cell killing and a stress-related response,
especially at the higher concentrations, cells treated as shown
in Fig. 3A were counted, and the protein content of the cellular
lysate was compared to the cell number. We have found that
there is a linear relationship between cell number and protein
concentration (data not shown); we therefore routinely deter-
mined protein concentration as a measure of cell growth.
These data are graphed normalizing the protein content (or cell
number) of the untreated sample to 1.0 to readily compare one
experiment with another. As can be seen in Fig. 3B, when cells
are treated with MTX alone (group C) cell growth is blocked
completely by MTX at 0.025 ,ug/ml, and very little additional
effect on cell number is seen at the higher concentrations,
where there is a dose-dependent increase in CAT activity (Fig.
3A, group C). From 0.025 to 0.2 gg/ml, the cell number is
-20% of the untreated sample. This result is consistent with
blocked cell growth during the 48-hr treatment, since during
this period the cell number of the untreated sample increased
5-fold, corresponding to 2.3 doublings. Thus, within the range
where a linear relationship between drug concentration and
promoter activity is observed, MTX blocked proliferation
equally but did not kill cells. Addition of the various metab-
olites did not equivalently affect proliferation and DHFR
promoter activity, suggesting that the effect ofMTX on DHFR
transcription is not due simply to inhibition of cell growth.
Effect of Other Inhibitors of DNA Synthesis. To determine
if the DHFR promoter was stimulated by other inhibitors of
DNA synthesis and cell growth, we tested the effect of three
other agents on the DHFR promoter. Cells were transfected
with pDHF/CAT and treated with aphidicolin (10-100 ,ug/
ml), an inhibitor of DNA polymerase a. Aphidicolin blocked
cell proliferation (Fig. 4B), but had no effect on CAT expres-
sion from the DHFR promoter (Fig. 4A). The effects of two
other antimetabolites on the DHFR promoter were also
tested. Fluorodeoxyuridine, an inhibitor of thymidylate syn-
thetase, stimulated the DHFR promoter in a concentration-
dependent manner (Fig. SA). Hydroxyurea, an inhibitor of
ribonucleotide reductase, in the range of 0.05-1 mM, also
stimulated theDHFR promoter in a concentration-dependent
manner to a maximum of 2.5-fold (Fig. SC). Both of these
agents inhibited cell growth (Fig. 5 B and D), although not as
completely as MTX or aphidicolin.
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FIG. 3. Effect of 5-methyltetrahydrofolate (H4F), hypoxanthine
(HX), and/or thymidine (Thy) on MTX stimulation of the DHFR
promoter and on cell growth. CHO cells were transfected with
pDHF/CAT (5 ,ug) by the calcium phosphate transfection method.
Four hours later, the following reagents were added to the medium
as indicated: 0.025-0.2 ,ug of MTX per ml; 2 jAM H4F; 17.6,uM HX;
100 AtM Thy. All agents were added at 0 and 24 hr. C, control
(treatment with MTX alone). (A) Results of the CAT assay performed
using equal amounts of protein in cell lysates 48 hr after transfection.
For each treatment group, CAT activity for cells not treated with
MTX was assigned a relative value of 1. Absolute values for CAT
activity in this experiment ranged from 12 pmol of acetylated product
formed per /Ag of protein in the untreated control to 99.5 pmol/g at
0.20 jtg of MTX per ml. (B) Effect of these treatments on cell growth.
Protein concentrations in the cellular lysates were determined by the
Bradford assay (20) and normalized to a control value of 1.0 as
described for CAT assays. Protein concentration is a measure of cell
number as discussed in Results. These results are representative of
three repetitions of this experiment. Two-way analysis of variance
(ANOVA) of the data inA revealed that the MTX-treated samples are
significantly different from one another and from the untreated
sample (P c 0.05) at all of the concentrations tested. Furthermore,
the addition of H4F, HX, or HX plus Thy with MTX at all of the
concentrations eliminated this difference (P s 0.05), whereas the
addition of Thy had no significant effect as compared with MTX
alone at all of the concentrations tested, with the exception of 0.2 ,ug
of MTX per ml (P c 0.05).
Taken together, these data suggest that DHFR promoter
activity is significantly stimulated in cells treated with MTX,
hydroxyurea, and fluorodeoxyuridine. This stimulation is not
simply the result of inhibition of DNA synthesis and cell
proliferation; aphidicolin, which blocks proliferation as ef-
fectively as MTX, does not affect promoter activity. Fur-
thermore, MTX stimulation of CAT activity is dose depen-
dent at drug concentrations that have an equal antiprolifer-
ative effect.
DISCUSSION
We have explored the response of the DHFR promoter to
MTX, and to other inhibitors of DNA synthesis, and found
that MTX as well as the antimetabolites fluorodeoxyuridine
and hydroxyurea stimulate the DHFR promoter, whereas
Proc. Natl. Acad. Sci. USA 88 (1991)
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FIG. 4. Effect of aphidicolin (APC) on transient expression from
the DHFR promoter and on cell growth. CHO cells were transfected
with pDHF/CAT (5 Eg) by the calcium phosphate transfection
method. Four hours later, APC was added at the indicated concen-
trations. An equal volume ofDMSO, which was the vehicle for APC,
was added to a duplicate transfected plate. Cells were harvested and
lysates were prepared and assayed for protein concentration and
CAT activity. (A) CAT activity in cells treated with the indicated
concentration of APC, after subtracting the effect of DMSO alone.
DMSO stimulated CAT activity up to 2-fold at the highest amount
(100 Aul in 10 ml). The absolute value ofCAT activity was conversion
of 7.8 pmol of acetyl CoA per jug of cellular lysate in the control and
the treated samples. These results are representative of three repe-
titions of this experiment. Two-way ANOVA revealed no significant
differences in CAT activity between the APC-treated samples and
the control at any of the APC concentrations tested (P < 0.05). (B)
Relative protein content of the cellular lysates at the indicated
concentration of APC, which was directly related to cell number.
Cell number was 1o of control at the highest concentration ofAPC.
aphidicolin has no effect. DHFR enzyme levels have been
shown by others to be elevated in response to acute treatment
of cells with MTX (2-4). The most common mechanism by
which DHFR enzyme is overproduced in MTX-resistant cells
is thought to be gene amplification; however, it is clear from
our studies that there may also be an induction of DHFR
transcription in response to MTX treatment of cells.
Since DHFR plays an essential role in metabolism, we
examined some possible metabolic signals that could mediate
enhanced DHFR transcription. DHFR is the only enzyme
capable ofregenerating intracellular pools of reduced folates,
which are cofactors for glycine, purine, and thymidine bio-
synthesis. Therefore, inactivation ofDHFR by MTX leads to
lower cellular tetrahydrofolate levels and subsequent reduc-
tion of cell growth (25). The effects ofMTX can be overcome
by 5-methyltetrahydrofolate (26). Addition of 5-methyltet-
rahydrofolate blocked the stimulation ofCAT activity and the
inhibition of cell growth by MTX. Since the effect of folate
could have been the result of decreased uptake of MTX (22,
23), we also examined the effect of addition of intermediates
whose biosynthesis is blocked by MTX. Addition of hypo-
xanthine alone or of both thymidine and hypoxanthine com-
pletely prevented the stimulation, whereas addition of thy-
midine alone reduced the stimulation from 8-fold to 2-fold.
Hypoxanthine and thymidine separately partially blocked the
antiproliferative effect of MTX, whereas addition of both
hypoxanthine and thymidine restored normal growth. These
results suggest that the antiproliferative effect of MTX and
the effect ofthe drug onDHFR transcription are not mediated
by completely overlapping mechanisms.
We also examined the ability of three other DNA synthesis
inhibitors-aphidicolin, hydroxyurea, and fluorodeoxyuri-
dine-to stimulate transcription of the DHFR promoter.
Aphidicolin blocks DNA replication by inhibition of DNA
polymerase a. Fluorodeoxyuridine is an inhibitor of thymi-
dylate synthetase, and hydroxyurea inhibits ribonucleotide
reductase. Aphidicolin did not affect the DHFR promoter,
whereas hydroxyurea and fluorodeoxyuridine stimulated
DHFR transcription. All of these agents had an antiprolifer-
ative effect, suggesting that inhibition of cell growth is not the
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FIG. 5. Effect of fluorodeoxyuridine (FUdR) and hydroxyurea
(HU) on the DHFR promoter. CHO cells transfected with pDHF/
CAT (5 Ag) by the calcium phosphate transfection method were
treated for 48 hr with FUdR or HU at the indicated concentrations.
Cellular lysates were assayed for protein concentration and CAT
activity. Data shown are from one experiment; these results have
been observed in three separate experiments with the range of
induction with both drugs being 2- to 3-fold. (A) Effect of FUdR on
CAT activity; the range of activity was 14.9 pmol of acetylated
product formed per ug of protein in the control to 31.9 pmol/,ug of
protein in the cells treated with 5 ALM FUdR. Two-way ANOVA
demonstrated a significant effect of FUdR on CAT activity at 1 and
5 ,tM vs. control (P c 0.05). (B) Effect of FUdR on cell growth; the
absolute values were 3.3 Aug/ml in the untreated sample and 1.5
jug/ml in the cells treated with 5 .tM FUdR. This represents -50%o
inhibition of growth; complete growth inhibition was not observed
even at higher drug concentrations. (C) Effect of HU on CAT
expression. In this experiment the untreated cells converted 14.9
pmol of [3H]acetyl CoA per ag of protein and cells treated with 1 mM
HU converted 35.8 pmol/i&g. Two-way ANOVA demonstrated a
significant effect of HU at 0.5 and 1 mM vs. control (P < 0.07). (D)
Cell growth was inhibited 50%, equivalent to the effect of FUdR.
mechanism by which the three antimetabolic agents (MTX,
fluorodeoxyuridine, and hydroxyurea) stimulate transcrip-
tion. Since the three agents that we found stimulated the
DHFR promoter are inhibitors of nucleotide biosynthesis, it
is possible that stimulation of DHFR transcription occurs
through a common pathway. The promoters for thymidylate
synthetase (27) and ribonucleotide reductase (28), like
DHFR, have multiple GC boxes (putative Spl binding sites),
and thymidylate synthetase, like DHFR, lacks both TATAA
and CCAAT motifs. We have shown that the GC boxes ofthe
hamsterDHFR promoter control the rate oftranscription and
start site selection (11, 12). It is interesting to speculate that
all of these drugs may affect common transcription factors to
activate transcription of a class of genes.
The DHFR promoter fragment used in the described ex-
periments contains 40 bp 3' to the major start oftranscription
that could conceivably contribute to specific posttranscrip-
tional effects on CAT mRNA since this sequence is present
in the DHFR transcripts. Within this 40-nucleotide region,
the only sequence element conserved among the hamster,
mouse, and human genes is the region corresponding to a
binding site for the transcription factor E2F. Although mu-
tation of the E2F region has been shown to affect transcrip-
tion (13), there is no evidence to support a role for E2F in
binding to RNA or stabilizing RNA. A mutation that abol-
ished E2F interaction with the E2F sites decreased basal
promoter activity but did not affect relative MTX inducibility
HH\nN
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(data not shown). The CAT coding sequence, simian virus 40
region, and plasmid vector are identical in both the DHFR
CAT construct and the AdMLP/CAT construct, which in
these studies did not respond to MTX. Taken together, these
data suggest that MTX inducibility is not conferred byDHFR
promoter sequence 3' to the start of transcription. Additional
posttranscriptional or other effects ofMTX onDHFR expres-
sion in cells are possible but do not appear to be involved in
the response observed in this study. Experiments are nec-
essary- to identify the specific DHFR promoter element that
mediates the effect of MTX and to study the effect of MTX
on the factor that binds to this element.
The fact that MTX and other antimetabolites can increase
transcription from theDHFR promoter is potentially relevant
to the issue of cellular cross-resistance to chemotherapeutic
agents. Cross-resistance to drugs is a confounding problem in
cancer chemotherapy; the clinical approach has been to
empirically combine chemotherapeutic agents. It is clear that
selection of cells for resistance to two different drugs results
in a frequency of cross-resistance that is often much greater
than the product of the two individual frequencies (29, 30).
There are many possible mechanisms by which cross-
resistance can arise. We propose a mechanism whereby
several different drugs increase the activity or level of a
common transcription factor, which could then stimulate
transcription of a range of genes with common promoter
elements. Cells that are resistant to these agents may have
increased the basal activity of this transcription factor(s),
which would enable them to circumvent the inhibitory effects
of a range of drugs by increasing the transcription of genes
whose products are inhibited.
Our data are consistent with the hypothesis that elevated
DHFR transcription may be an early response to MTX
treatment. Stimulation of DHFR- transcription by MTX
would provide a mechanism to increase enzyme levels prior
to gene amplification. The increased transcription ofthe gene
could be directly involved in subsequent gene amplification.
This hypothesis is supported by the observation that several
of the agents that increase DHFR mRNA levels also increase
the frequency of gene amplification (refs. 4, 10, 31; J.C.A.
and A.G.S., unpublished). It has been reported that the
increase in gene amplification in response to hydroxyurea is
prevented by simultaneous addition of cycloheximide, sug-
gesting that a factor that facilitates gene amplification is
stimulated during the treatment (10). Furthermore, transcrip-
tionally active genes are better templates for recombination
(32-35) and DNA repair (36) and may be better templates for
the process of gene amplification.
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